A New Approach for the Treatment of COPD and Lung Cancer using Inhaled Retrometabolic HSP90 Inhibitors [ 2012 - 2015 ]

Research Grant

Researchers: A/Pr Christopher Burns (Principal investigator) ,  Dr Marie-Liesse Asselin-Labat ,  Prof Gary Anderson

Brief description The inflammatory lung disease Chronic Obstructive Pulmonary Disease (COPD) is a major disease burden in Australia with over 1 million sufferers and being the fourth biggest killer. Lung cancer is one of the most difficult cancers to treat with 5-year survival rates being below 20%. There is a pressing need for new therapies to treat these diseases and this project will develop new drugs designed to inhibit an underlying mechanism present in both diseases, with minimal side-effects.

Funding Amount $AUD 638,310.84

Funding Scheme Development Grants

Notes Development Grant